Edition:
United States

Hybrigenics SA (ALHYG.PA)

ALHYG.PA on Paris Stock Exchange

0.60EUR
22 Sep 2017
Change (% chg)

€0.01 (+1.69%)
Prev Close
€0.59
Open
€0.59
Day's High
€0.60
Day's Low
€0.59
Volume
120,402
Avg. Vol
255,992
52-wk High
€1.01
52-wk Low
€0.52

Latest Key Developments (Source: Significant Developments)

Hybrigenics raises 6.8 million euros in capital increase
Monday, 24 Jul 2017 11:53am EDT 

July 24 (Reuters) - HYBRIGENICS SA ::RAISES EUR 6.8 MILLION IN CAPITAL INCREASE.TO ISSUE 10,957,950 NEW SHARES.GLOBAL DEMAND OF EUR 8.8 MILLION.TRADING OF NEW SHARES TO START ON JULY 27 ON EURONEXT PARIS.PRICE IS EUR 0.62 PER NEW SHARES.  Full Article

Hybrigenics gets european patent protection for inhibitors of ubiquitin-specific protease 8
Wednesday, 7 Jun 2017 02:28am EDT 

June 7 (Reuters) - HYBRIGENICS SA ::HYBRIGENICS GETS EUROPEAN PATENT PROTECTION FOR INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 8 (USP8).  Full Article

Hybrigenics gets European patent protection for inhibitors of USP8
Tuesday, 6 Jun 2017 12:34pm EDT 

June 6 (Reuters) - HYBRIGENICS SA ::HYBRIGENICS GETS EUROPEAN PATENT PROTECTION FOR INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 8 (USP8).  Full Article

Hybrigenics FY operating loss of 4.3 million euros
Friday, 28 Apr 2017 01:05pm EDT 

April 28 (Reuters) - Hybrigenics SA ::Fy net loss of 5.3 million euros ($5.78 million) versus loss of 4.3 million euros year ago.Fy revenue 2.5 million euros versus 1.2 million euros year ago.Cash position at end of year 8.5 million euros versus 11.1 million euros year ago.Fy operating loss 4.3 million euros versus loss 5.0 million euros year ago.  Full Article

Hybrigenics FY revenue rises to 2.5 million euros
Monday, 13 Mar 2017 01:25pm EDT 

Hybrigenics SA : Cash position of 8.8 million euros as of Dec. 31, 2016 .FY revenue 2.5 million euros versus 1.2 million euros year ago.  Full Article

Hybrigenics announces results from Phase II study on inecalcitol
Thursday, 9 Feb 2017 12:37pm EST 

Hybrigenics SA : Announces encouraging preliminary results from the Phase II clinical study of inecalcitol in Chronic Myelogenous Leukemia . At this intermediate stage of study, 43 percent of the patients (6 out of 14) have shown further decrease in bcr-abl from mmr at three months . After one year of treatment, 33 percent (3 out of 9) have demonstrated reduction in BCR-ABL beyond DMR, i.e. undetectable biomarker traces .The sample size of this pilot study has been reduced to 42 patients, with a target completion in H2 2018.  Full Article

Hybrigenics H1 net loss widens to 2.9 million euros
Tuesday, 25 Oct 2016 01:08pm EDT 

Hybrigenics SA : H1 net loss 2.9 million euros ($3.16 million) versus loss of 2.3 million euros year ago . H1 operating loss of 2.9 million euros versus loss of 2.4 million euros year ago .H1 revenue from scientific services 1.7 million euros versus 1.5 million euros year ago.  Full Article

Hybrigenics gets FDA approval for inecalcitol phase II study
Monday, 11 Jan 2016 12:16pm EST 

Hybrigenics SA:Receives FDA approval for phase II clinical study of inecalcitol in acute myeloid leukemia in the United States.  Full Article

Hybrigenics gets authorization for clinical Phase II study of inecalcitol
Monday, 14 Dec 2015 11:47am EST 

Hybrigenics SA:Receives green light for a clinical Phase II double blind study against placebo of inecalcitol in acute myeloid leukemia.Authorization received from national agency for the security of medicines in France.  Full Article